Tolcapone

CAS No:
134308-13-7 Categories: , ,
  • #LGM Pharma is a Tolcapone CAS# 134308-13-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 134308-13-7
  • AHFC code:
  • Synonyms:
  • ATC Code: N04BX01
  • Chemical Formula: C16H14F3NO3S
  • Molecular Weight: 273.2408
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00323 (APRD00445)
  • SMILES: CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O
  • InChl: MIQPIUSUKVNLNT-UHFFFAOYSA-N
  • PubChem: 4659569
  • IUPAC: 5-[(4-methylphenyl)carbonyl]-3-nitrobenzene-1,2-diol

Additional Details

Indication:
Used as an adjunct to levodopa/carbidopa therapy for the symptomatic treatment of Parkinson's Disease. This drug is generally reserved for patients with parkinsonian syndrome receiving levodopa/carbidopa who are experiencing symptom fluctuations and are not responding adequately to or are not candidates for other adjunctive therapies.
Pharmacodynamics:
Tolcapone is a potent, selective, and reversible inhibitor of catechol-O-methyltransferase (COMT). In humans, COMT is distributed throughout various organs. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. COMT is responsible for the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa catalyzing it to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery. When tolcapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that these sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease in patients as well as increased levodopa adverse effects, sometimes requiring a decrease in the dose of levodopa.
Mode of Action:
The precise mechanism of action of tolcapone is unknown, but it is believed to be related to its ability to inhibit COMT and alter the plasma pharmacokinetics of levodopa, resulting in an increase in plasma levodopa concentrations. The inhibition of COMT also causes a reduction in circulating 3-OMD as a result of decreased peripheral metabolism of levodopa. This may lead to an increase distribution of levodopa into the CNS through the reduction of its competitive substrate, 3-OMD, for transport mechanisms. Sustained levodopa concentrations presumably result in more consistent dopaminergic stimulation, resulting in greater reduction in the manifestations of parkinsonian syndrome.
Metabolism:
The main metabolic pathway of tolcapone is glucuronidation
Toxicity:
LD50 = 1600 mg/kg (Orally in rats)
General Reference:
Guay DR: Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinsonês disease. Pharmacotherapy. 1999 Jan;19(1):6-20. Pubmed Keating GM, Lyseng-Williamson KA: Tolcapone: a review of its use in the management of Parkinsonês disease. CNS Drugs. 2005;19(2):165-84. Pubmed Truong DD: Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinsonês disease. Clin Interv Aging. 2009;4:109-13. Epub 2009 May 14. Pubmed Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506. Pubmed Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinsonês disease. Drugs. 2000 Jun;59(6):1233-50. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos